The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy

PCSK9 inhibitors (PCSK9i) are monoclonal antibodies that have been shown to be effective in reducing both LDL cholesterol (LDL-C) values and major cardiovascular events in patients at high cardiovascular risk. Adherence to PCSK9i is critical for the success of the treatment. The aim of the present s...

Descripción completa

Detalles Bibliográficos
Autores principales: Caso, Valentina Maria, Sperlongano, Simona, Liccardo, Biagio, Romeo, Emanuele, Padula, Sergio, Arenga, Fortunato, D’Andrea, Antonello, Caso, Pio, Golino, Paolo, Nigro, Gerardo, Russo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836402/
https://www.ncbi.nlm.nih.gov/pubmed/35159928
http://dx.doi.org/10.3390/jcm11030475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836402/
https://www.ncbi.nlm.nih.gov/pubmed/35159928
http://dx.doi.org/10.3390/jcm11030475

Ejemplares similares